Treatment Refractory Soft Tissue Myoepithelial Carcinoma With an ARID1A Mutation

J Pediatr Hematol Oncol. 2023 May 1;45(4):e539-e542. doi: 10.1097/MPH.0000000000002650. Epub 2023 Mar 13.

Abstract

Soft tissue myoepithelial carcinoma is a rare tumor first reported in the salivary gland. There is considerable tumor heterogeneity between pathology findings, tumor aggressiveness, and response to treatment. Recent molecular testing has identified recurrent genetic changes with PLAG mutations in salivary gland primary tumors and loss of SMARCB1 and EWSR1/FUS gene changes in myoepithelial carcinoma. SMARCB1 is a component of the switch/sucrose nonfermentable (SWI/SNF) complex, an essential cellular regulator. ARID1A is another SWI/SNF complex subunit and is a potent oncogenic driver in other tumor types. In this case, we describe the case of an adolescent/young adult patient with treatment refractory soft tissue myoepithelial carcinoma and a previously unreported ARID1A mutation.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Carcinoma* / genetics
  • DNA Helicases / genetics
  • DNA-Binding Proteins / genetics
  • Humans
  • Mutation
  • Nuclear Proteins* / genetics
  • SMARCB1 Protein / genetics
  • Transcription Factors / genetics
  • Young Adult

Substances

  • Nuclear Proteins
  • DNA Helicases
  • SMARCB1 Protein
  • ARID1A protein, human
  • DNA-Binding Proteins
  • Transcription Factors